Ben Feldman, M.Med.Sc., with his extensive international healthcare background and expertise in performance and brand marketing, will spearhead AposHealth’s efforts to accelerate growth and expand its revolutionary non-invasive treatment nationwide presence.
“At this point, we have proved the value proposition of Apos® for payors, providers and patients. All stakeholders see Apos® as a game changer in treating MSK conditions,” says Cliff Bleustein, MD, MBA, President and CEO of AposHealth®. “We are happy to announce the addition of Ben Feldman as a Senior Vice President and Chief Marketing Officer to help build out AposHealth® nationally. His proven track record of scaling international healthcare companies will help us catapult forward into our next phase of growth.”
Ben Feldman, who holds a Master’s in Medical Sciences and has authored several academic publications, brings a wealth of experience as a seasoned marketing professional with a deep clinical understanding and an international perspective. His career is marked by transformative growth in the health and e-commerce sectors through strategic business-to-business (B2B), direct-to-consumer (DTC), and business-to-business-to-consumer (B2B2C) marketing approaches. His professional expertise spans traditional and digital marketing, brand management and development, research and integration of innovative marketing technologies.
Throughout his career, Feldman has led the expansion of multiple international healthcare and e-commerce brands, focusing on performance and market penetration. A notable achievement includes his leadership in the marketing and initial sales phases of the groundbreaking medical device Vibrant. His efforts were crucial in navigating the product from pre-FDA approval to its successful launch as a fully approved and commercially available product.
“Bringing innovative treatments to patients in need transcends just a job—it gives profound meaning to life. I am eager to leverage my skills to introduce Apos® to those with musculoskeletal conditions, helping them benefit from Apos® and live their lives to the fullest,” says Feldman.
About AposHealth®
We at AposHealth® are passionate about revolutionizing the treatment of musculoskeletal conditions by simply addressing peoples’ gait to help alleviate pain and help them move and live better. Our flagship solution, Apos®, is CE-marked, NICE-recommended and FDA-cleared to temporarily reduce knee pain caused by osteoarthritis. It can also be used as a general wellness device to help patients live well with lower back and hip pain.
With over 150,000 patients treated and over 70 peer-reviewed publications supporting the science behind Apos® and its clinical effect, this program—consisting of gait analysis, personalized foot-worn medical device, and customized treatment plan—has helped patients worldwide move, live, and thrive.
Apos® is available in the US and is covered by many insurance plans, as well as across the NHS through the NHS supply chain. For more information, visit aposhealth.com or aposhealth.co.uk.
